Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;236(4):2519-2543.
doi: 10.1002/jcp.30076. Epub 2020 Oct 6.

Immunobiology and immunotherapy of COVID-19: A clinically updated overview

Abdolreza Esmaeilzadeh  1   2   3 , Reza Elahi  4
Affiliations
Review

Immunobiology and immunotherapy of COVID-19: A clinically updated overview

Abdolreza Esmaeilzadeh et al. J Cell Physiol. 2021 Apr.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new member of the coronavirus family that can cause coronavirus disease 2019 (COVID-19). COVID-9 has become a global pandemic with severe health issues around the world. Identifying the accurate immunopathogenesis of the COVID-19 and the immune response against SARS-CoV-2 is necessary for the development of therapeutic approaches and rational drug design. This paper aims to overview the updated clinical data on the immunopathogenesis of the COVID-19 and review the innate and adaptive immune response to SARS-CoV-2. Also, challenges of the immune response to SARS-CoV-2 leading to dysfunctional immune response and their contribution to the progression of the disease have been discussed. To achieve a more efficient immune response, multiple methods could be applied, including regulation of the immune response, augmentation of the immune system against the virus, inhibition of the dysfunctional immune checkpoints, and inhibition of the viral replication/infection. Based on the immune response against SARS-CoV-2 and its dysfunction, we introduce potential immunotherapies as well as reviewing recruiting/completed clinical trials of COVID-19.

Keywords: COVID-19; SARS-CoV-2; clinical trial; immunopathogenesis; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflict of interests.

Figures

Figure 1
Figure 1
Immunotherapeutic approaches for COVID‐19. (Created by Esmaeilzadeh et al.) aAPC, artificial antigen‐presenting cell; BCG, Bacille Calmette–Guérin; CAR NK cell, chimeric antigen receptor natural killer cell; CCR5, CC chemokine receptor 5; CD14, cluster of differentiation 14; DC, dendritic cell; DNA, deoxyribonucleic acid; GM‐CSF, granulocyte‐macrophage colony‐stimulating factor; IFN‐γ, interferon‐γ; IL, interleukin; IVIG, intravenous immunoglobulin; JAK, Jasus kinase; MSC, mesenchymal stem cell; NK cell, natural killer cell; PD‐1, programmed death‐1; RNA, ribonucleic acid; Tim‐3, T‐cell immunoglobulin and mucin‐domain containing‐3; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor
See this image and copyright information in PMC

References

    1. Amanat, F. , & Krammer, F. (2020). SARS‐CoV‐2 vaccines: Status report. Immunity, 52, 583–589. - PMC - PubMed
    1. Antonioli, L. , Fornai, M. , Pellegrini, C. , & Blandizzi, C. (2020). NKG2A and COVID‐19: Another brick in the wall. Cellular & Molecular Immunology, 17, 672–674. 10.1038/s41423-020-0450-7 - DOI - PMC - PubMed
    1. Arenas, M. , Sabater, S. , Hernández, V. , Rovirosa, A. , Lara, P. , Biete, A. , & Panes, J. (2012). Anti‐inflammatory effects of low‐dose radiotherapy. Strahlentherapie und Onkologie, 188(11), 975–981. - PubMed
    1. Azimi, S. , Sahebnasagh, A. , Sharifnia, H. , & Najmeddin, F. (2020). Corticosteroids administration following COVID‐19‐induced acute respiratory distress syndrome. Is it harmful or life‐saving? Advanced Journal of Emergency Medicine, 4(2s):e43.
    1. Bachanova, V. , Bishop, M. R. , Dahi, P. , Dholaria, B. , Grupp, S. A. , Hayes‐Lattin, B. , Janakiram, M. , Maziarz, R. T. , McGuirk, J. P. , Nastoupil, L. J. , Oluwole, O. O. , Perales, M. A. , Porter, D. L. , Riedell, P. A. , & CAR T‐cell Consortium (2020). CAR T cell therapy during the COVID‐19 pandemic. Biology of Blood and Marrow Transplantation, 26, 1239–1246. - PMC - PubMed